advanced SOFT TISSUE SARCOMA Soft tissue sarcoma (STS) is a malignant tumor of connective tissue, accounting for about 1% OF ALL HUMAN CANCERS.

STS can develop from soft tissues like fat, muscle, nerves, SOME SIGNS AND SYMPTOMS OF aSTS fibrous tissues, blood vessels or deep skin tissues MAY INCLUDE:

fat

nerves Increasing A new lump or a lump blood vessels abdominal pain that is growing (anywhere on the body)

muscle

fibrous tissues

Blood in the stool or vomit

MORE THAN HALF DEVELOP Black, tarry stools IN THE ARMS OR LEGS

MOST COMMON PRIMARY SITES OF STS

EXTREMITIES INTERNAL ORGANS RETROPERITONEUM THE TRUNK HEAD AND NECK 43% 19% 15% 10% 9% THE LUNGS ARE THE MOST COMMON (CONTAINS THE KIDNEYS, PANCREAS SITE OF METASTASIS IN PATIENTS AND PART OF THE HEART) WITH STS OF THE EXTREMITIES

approximately The 5-year Patients with aSTS have a poor prognosis, OF SURVIVAL RATE with a median overall survival (OS) of 50% PATIENTS are diagnosed with or expected for aSTS is 8 TO 12 MONTHS to progress to advanced or from time of advanced diagnosis metastatic disease (aSTS) 16%

DIAGNOSIS

ULTRASOUND may be the first exam, but it should be followed by a CT or MRI

Following appropriate imaging assessment, the standard approach to diagnosis consists of multiple core needle biopsies

MANAGEMENT OF aSTS

A MULTIDISCIPLINARY APPROACH is recommended, which can include support from pathologists, radiologists, surgeons, radiation therapists, medical oncologists as well as nuclear medicine specialists and organ specialists.

SURGERY RADIATION THERAPY SYSTEMIC THERAPY TARGETED THERAPIES • surgery is the most • chemotherapy and • conventional cytotoxic • these therapies aim common first treatment radiation treatment chemotherapy is the to disrupt the for sarcomas that are small options may standard treatment cancer’s cell growth and in specific locations be combined option for aSTS patients and survival

Novartis Pharma AG CH-4002 Basel Switzerland ©Novartis 2016 January 2016 G-VOT-1131077